Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Company Deals

Pakistan-China Pharma Pact: $440M in Agreements Positions Pakistan as Regional Medicines Hub

Fineline Cube Jul 24, 2026
Company Deals

Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma

Fineline Cube Jul 23, 2026
Company Deals

Shanghai Pharmaceuticals Commits $42M to SIIC Bio-Med Fund Targeting FIC/BIC Assets from IND to Phase II

Fineline Cube Jul 22, 2026
Company Deals

TYK Medicines and Qilu Pharmaceutical Forge Strategic Partnership for EGFR-TKI TY-9591 with $2.4B Deal

Fineline Cube Jul 22, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

Walvax Biotechnology’s Bivalent HPV Vaccine WALRINVAX Gains Tanzanian Approval Following WHO Prequalification

Fineline Cube Jul 24, 2026
Company Drug

Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance

Fineline Cube Jul 24, 2026
Company

Milestone Biotechnologies Secures Nearly 100 Million Yuan in Series A+ Funding

Fineline Cube Jan 5, 2025

Milestone Biotechnologies, a leading biotechnology company based in Shanghai, has announced the completion of a...

Company Drug

AstraZeneca’s Tagrisso Receives NMPA Approval for EGFR-Mutated NSCLC Treatment

Fineline Cube Jan 3, 2025

UK-based AstraZeneca (AZ, NASDAQ: AZN) has announced that it has received a new indication approval...

Company Drug

NMPA Approves Lynparza as Adjuvant Treatment for High-Risk Breast Cancer Patients

Fineline Cube Jan 3, 2025

The National Medical Products Administration (NMPA) in China has granted AstraZeneca (AZ, NASDAQ: AZN) and...

Company Drug

Gilead Sciences’ Sunlenca Receives NMPA Approval for Multidrug-Resistant HIV-1 Infection

Fineline Cube Jan 3, 2025

US-based pharmaceutical company Gilead Sciences Inc., (NASDAQ: GILD), has announced that it has received marketing...

Company Drug

WinHealth Pharma’s Difelikefalin Receives NMPA Review for Market Approval

Fineline Cube Jan 3, 2025

China-based Hong Kong WinHealth Pharma Group has announced that the National Medical Products Administration (NMPA)...

Policy / Regulatory

Shanghai Enacts New Regulations for Drug and Medical Device Administration

Fineline Cube Jan 3, 2025

The Standing Committee of the Shanghai Municipal People’s Congress has approved and released the “Regulations...

Company Drug

Thederma’s TAN-118 Receives Tacit Clinical Approval from China’s CDE for Global Trials

Fineline Cube Jan 3, 2025

Shanghai-based Thederma has announced that its drug candidate TAN-118 has obtained tacit clinical approval from...

Company Deals

Shenzhen Hepalink Pharmaceuticals to Distribute Gabapentin in US under New Agreement

Fineline Cube Jan 3, 2025

China-based Shenzhen Hepalink Pharmaceutical Group Co., Ltd (SHE: 002399, HKG: 9989) has announced a product...

Company Drug

Innovent Biologics’ Taletrectinib Gains NMPA Approval for ROS1 Positive NSCLC

Fineline Cube Jan 3, 2025

China-based Innovent Biologics, Inc. (HKG: 1801) has announced receiving an additional marketing approval from the...

Company Drug

MabPharm’s CMAB807 Biosimilar Infliximab Approved in Pakistan

Fineline Cube Jan 3, 2025

Taizhou-based monoclonal antibody (mAb) biosimilar specialist MabPharm Ltd (HKG: 2181) has announced the receipt of...

Company Drug

Zhaoke Ophthalmology’s NVK002 ANDA Accepted for Review by China’s NMPA

Fineline Cube Jan 3, 2025

China-based Lee’s Pharmaceutical Holdings Ltd’s (HKG: 0950) former subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has...

Company Medical Device

Grand Pharmaceutical Initiates Study on GPN00289 for Liver Cancer Treatment

Fineline Cube Jan 3, 2025

China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) has announced the first patient enrollment in...

Company Drug

SCG Cell Therapy’s SCG142 Receives NMPA Approval for HPV-Related Solid Tumor Clinical Trial

Fineline Cube Jan 3, 2025

SCG Cell Therapy Pte. Ltd, a Singapore-based company with a presence in Shanghai, has received...

Company Drug

Huadong Medicine’s HDM1005 Receives NMPA Approval for MAFLD/MASH Clinical Trial

Fineline Cube Jan 3, 2025

Huadong Medicine Co., Ltd (SHE: 000963) has announced that it has received clinical trial approval...

Company Deals

Cygenta Partners with IZVARINO Pharma for Comprehensive CDMO Services

Fineline Cube Jan 3, 2025

Cygenta, a cell and gene therapy (CGT) focused Contract Development and Manufacturing Organization (CDMO) based...

Company Deals

Pfizer Collaborates with Atavistik Bio to Discover Allosteric Therapeutics

Fineline Cube Jan 3, 2025

US pharmaceutical giant Pfizer (NYSE: PFE) has entered into a research collaboration with compatriot firm...

Company Drug

NMPA Grants Conditional Approval for China’s First MSCs Therapy for aGVHD

Fineline Cube Jan 3, 2025

The National Medical Products Administration (NMPA) in China has conditionally approved amimestrocel from Beijing-based Platinum...

Company Medical Device

Genesis MedTech’s iReach Omnia Receives NMPA Approval for Rectal Cancer Surgery

Fineline Cube Jan 2, 2025

Singapore-based medical device company Genesis MedTech has announced that it has received marketing approval from...

Company Drug

Eli Lilly & Co. Launches Mounjaro (Tirzepatide) in China for Diabetes and Weight Management

Fineline Cube Jan 2, 2025

US pharmaceutical major Eli Lilly & Co. (NYSE: LLY) has announced the official market launch...

Company Deals

Prime Gene Therapeutics Secures Over RMB300 Million in Series B Financing

Fineline Cube Jan 2, 2025

Beijing-based Prime Gene Therapeutics Co., Ltd (873969.NQ), a clinical-stage biotech company specializing in immune inflammatory...

Posts pagination

1 … 268 269 270 … 699

Recent updates

  • Walvax Biotechnology’s Bivalent HPV Vaccine WALRINVAX Gains Tanzanian Approval Following WHO Prequalification
  • Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance
  • Changchun High-Tech Subsidiary GeneScience Files SLE Clinical Application for Novel Dual-Target BAFF/APRIL Inhibitor GenSci136
  • Lilly’s Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market
  • Aidea Pharma Secures NMPA Approval for Darunavir, Challenging J&J’s Prezista in China’s HIV Treatment Market
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Walvax Biotechnology’s Bivalent HPV Vaccine WALRINVAX Gains Tanzanian Approval Following WHO Prequalification

Company Drug

Kanghong Pharmaceutical Secures NMPA Approval for KHN921 Gene Therapy in MYBPC3-Related Hypertrophic Cardiomyopathy Following U.S. FDA Clearance

Company Drug

Changchun High-Tech Subsidiary GeneScience Files SLE Clinical Application for Novel Dual-Target BAFF/APRIL Inhibitor GenSci136

Company Drug

Lilly’s Retatrutide Delivers Up to 22.6% Weight Loss in Phase 3 Trials, Establishing Triple Agonist Leadership in Obesity Market

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.